In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole.
We determined MICs for 28 Candida isolates recovered from patients who developed breakthrough candidemia while receiving fluconazole. MICs correlated with daily and cumulative doses of fluconazole. Patients receiving > or =2,000 mg cumulatively or >200 mg daily were more likely to be infected with isolates that were not fluconazole susceptible.
Clancy
Cornelius J
CJ
University of Florida College of Medicine, Department of Medicine, Gainesville, FL 32610, USA. clancyn@medicine.ufl.edu
Staley
Benjamin
B
Nguyen
M Hong
MH
D000935:Antifungal Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001769:Blood / Q000382:microbiology; D002175:Candida / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D018890:Chemoprevention; D015725:Fluconazole / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D016469:Fungemia / Q000188:drug therapy* / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests
D000935:Antifungal Agents; D015725:Fluconazole